Overview

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Status:
Recruiting

Trial end date:
2025-02-10

Target enrollment:

Participant gender:

Summary

The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) and juvenile psoriatic arthritis (JPsA).

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Adalimumab
Ixekizumab